Brand name
Zestoretic, the original
We didn’t find a savings card or cash price from Zestoretic’s maker. Ask the pharmacy for Zestoretic’s cash price. With insurance, ask what your plan charges.
Generic name: lisinopril and hydrochlorothiazide
Used for: High blood pressure
From
$4 for 30 tablets
Generic lisinopril and hydrochlorothiazide at Walmart. Pick the strength on your label for its own price.
Rather have it mailed? From $8 a month from Rx Outreach, by mail. Make a free account, then have your prescription sent there.
Open Rx OutreachA regular generic has the same active ingredient as Zestoretic, and the FDA requires it to work the same way.
Zestoretic, the original
We didn’t find a savings card or cash price from Zestoretic’s maker. Ask the pharmacy for Zestoretic’s cash price. With insurance, ask what your plan charges.
There isn’t one.
Same active ingredient as Zestoretic. Fillers and dyes can differ.
Pharmacies’ own cash prices for generic lisinopril and hydrochlorothiazide, lowest first.
Pick up in storeDelivered
From each pharmacy’s own site, read November 17, 2026. Confirm the price before you fill.
Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.
5 companies sell a generic of Zestoretic that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
Has dyes: FD&C Red No. 40, FD&C Blue No. 2--aluminum lake · Made by Watson Laboratories
10 mg / 12.5 mg Pink, round, 8 mm, marked “WATSON / 860”
| Package | NDC |
|---|---|
| Bottle of 100 | 0591-0860-01 |
| Bottle of 500 | 0591-0860-05 |
20 mg / 12.5 mg Light blue, round, 10 mm, marked “WATSON / 861”
| Package | NDC |
|---|---|
| Bottle of 100 | 0591-0861-01 |
| Bottle of 500 | 0591-0861-05 |
20 mg / 25 mg Pink, round, 10 mm, marked “WATSON / 862”
| Package | NDC |
|---|---|
| Bottle of 100 | 0591-0862-01 |
| Bottle of 500 | 0591-0862-05 |
Inactive ingredients: silicon dioxide, dibasic calcium phosphate dihydrate, FD&C Red No. 40, magnesium stearate, mannitol, starch, corn, FD&C Blue No. 2--aluminum lake
Made by Invagen Pharmaceuticals
10 mg / 12.5 mg Peach, round, 6 mm, marked “IG / 446”
| Package | NDC |
|---|---|
| Bottle of 90 | 69097-968-05 |
| Bottle of 100 | 69097-968-07 |
| Bottle of 500 | 69097-968-12 |
| Bottle of 1000 | 69097-968-15 |
20 mg / 12.5 mg White to off-white, round, 8 mm, marked “IG / 447”
| Package | NDC |
|---|---|
| Bottle of 90 | 69097-969-05 |
| Bottle of 100 | 69097-969-07 |
| Bottle of 500 | 69097-969-12 |
| Bottle of 1000 | 69097-969-15 |
20 mg / 25 mg Peach, round, 8 mm, marked “IG / 448”
| Package | NDC |
|---|---|
| Bottle of 90 | 69097-971-05 |
| Bottle of 100 | 69097-971-07 |
| Bottle of 500 | 69097-971-12 |
| Bottle of 1000 | 69097-971-15 |
Inactive ingredients: anhydrous dibasic calcium phosphate, mannitol, starch, corn, magnesium stearate, ferric oxide yellow, ferric oxide red
Made by Invagen Pharmaceuticals
10 mg / 12.5 mg Pink, round, 6 mm, marked “IG / 446”
| Package | NDC |
|---|---|
| Bottle of 90 | 76282-446-90 |
| Bottle of 100 | 76282-446-01 |
| Bottle of 500 | 76282-446-05 |
| Bottle of 1000 | 76282-446-10 |
20 mg / 12.5 mg White to off-white, round, 8 mm, marked “IG / 447”
| Package | NDC |
|---|---|
| Bottle of 90 | 76282-447-90 |
| Bottle of 100 | 76282-447-01 |
| Bottle of 500 | 76282-447-05 |
| Bottle of 1000 | 76282-447-10 |
20 mg / 25 mg Pink, round, 8 mm, marked “IG / 448”
| Package | NDC |
|---|---|
| Bottle of 90 | 76282-448-90 |
| Bottle of 100 | 76282-448-01 |
| Bottle of 500 | 76282-448-05 |
| Bottle of 1000 | 76282-448-10 |
Inactive ingredients: anhydrous dibasic calcium phosphate, mannitol, starch, corn, magnesium stearate, ferric oxide yellow, ferric oxide red
Has a dye: FD&C Blue No. 2
12.5 mg / 10 mg Blue, hexagon (6 sided), 7 mm, marked “LL / B01”
| Package | NDC |
|---|---|
| Bottle of 100 | 68180-518-01 |
| Bottle of 500 | 68180-518-02 |
| Pouch of 5000 | 68180-518-30 |
12.5 mg / 20 mg Yellow, round, 8 mm, marked “LL / B02”
| Package | NDC |
|---|---|
| Bottle of 100 | 68180-519-01 |
| Bottle of 500 | 68180-519-02 |
| Pouch of 5000 | 68180-519-30 |
25 mg / 20 mg Orange, round, 8 mm, marked “LL / B03”
| Package | NDC |
|---|---|
| Bottle of 100 | 68180-520-01 |
| Bottle of 500 | 68180-520-02 |
| Pouch of 5000 | 68180-520-30 |
Inactive ingredients: anhydrous dibasic calcium phosphate, FD&C Blue No. 2, mannitol, starch, corn, magnesium stearate, aluminum oxide, ferric oxide yellow, ferric oxide red
Made by Prinston Pharmaceutical
10 mg / 12.5 mg White to off-white, round, 6 mm, marked “H150”
| Package | NDC |
|---|---|
| Bottle of 100 | 43547-420-10 |
| Bottle of 500 | 43547-420-50 |
| Bottle of 1000 | 43547-420-11 |
20 mg / 12.5 mg Yellow, round, 8 mm, marked “H151”
| Package | NDC |
|---|---|
| Bottle of 100 | 43547-421-10 |
| Bottle of 500 | 43547-421-50 |
| Bottle of 1000 | 43547-421-11 |
20 mg / 25 mg Pink mottled, round, 8 mm, marked “H152”
| Package | NDC |
|---|---|
| Bottle of 100 | 43547-422-10 |
| Bottle of 500 | 43547-422-50 |
| Bottle of 1000 | 43547-422-11 |
Inactive ingredients: dibasic calcium phosphate dihydrate, magnesium stearate, mannitol, starch, corn, ferric oxide yellow, ferric oxide red
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
“Before you fill my Zestoretic, can you tell me what I’d pay for the brand and for a generic?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
ZESTORETIC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ).
In using ZESTORETIC, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ).
In considering the use of ZESTORETIC, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Lisinopril ).
Source: the FDA label for Zestoretic (Almatica Pharma Inc.), March 31, 2025. Full label on DailyMed
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/zestoretic/